Pure Global

A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC - Trial NCT06383052

Access comprehensive clinical trial information for NCT06383052 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Norroy Bioscience Co., LTD and is currently Recruiting. The study focuses on Metastatic Castration-resistant Prostate Cancer. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06383052
Phase 1/2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06383052
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Radiation Dosimetry and Efficacy of 177Lu-NYM032 Injection in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Study Focus

177Lu-NYM032 injection

Interventional

drug

Sponsor & Location

Norroy Bioscience Co., LTD

Wuxi, China

Timeline & Enrollment

Phase 1/2

Apr 30, 2024

Nov 30, 2024

24 participants

Primary Outcome

Number of Patients With Dose Limiting Toxicity (DLT),Maximum Tolerated Dose (MTD)

Summary

177Lu-NYM032 injection is a radioligand therapeutic agent that targets prostate specific
 membrane antigen (PSMA)-expressing prostate tumors. NYM032 is a small molecular with strong
 affinity for PSMA.

ICD-10 Classifications

Malignant neoplasm of prostate
Hyperplasia of prostate
Carcinoma in situ: Prostate
Special screening examination for neoplasm of prostate
Dysplasia of prostate

Data Source

ClinicalTrials.gov

NCT06383052

Non-Device Trial